

AD _____

Award Number: DAMD17-01-1-0494

TITLE: Determining if EBV Infection Contributes to Breast
Carcinogenesis: Does LMP-1-mediated Upregulation of EGFR
and Bcl-x Affect Breast Cancer Pathogenesis?

PRINCIPAL INVESTIGATOR: Genhong Cheng, Ph.D.

CONTRACTING ORGANIZATION: University of California, Los Angeles
Los Angeles, California 90024-1406

REPORT DATE: July 2002

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20021231 117

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE July 2002	3. REPORT TYPE AND DATES COVERED Final (4 Jun 01 - 3 Jun 02)		
4. TITLE AND SUBTITLE Determining if EBV Infection Contributes to Breast Carcinogenesis: Does LMP-1-mediated Upregulation of EGFR and Bcl-x Affect Breast Cancer Pathogenesis?		5. FUNDING NUMBERS DAMD17-01-1-0494		
6. AUTHOR(S) Genhong Cheng, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of California, Los Angeles Los Angeles, California 90024-1406 E-Mail: genhongc@microbio.ucla.edu		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER		
11. SUPPLEMENTARY NOTES Report contains color				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) Most human breast cancer cells are derived from epithelial cells. Previously studies indicated that about 20% of breast cancer patients carrying tumor cells with overexpression of Her-2/Neu. Herceptin, an antagonist antibody against Her-2/Neu, has been used in clinic for the treatment of breast cancers overexpressing Her-2/Neu. We found that EGFR and Her-2/Neu are highly overexpressed in tumor cells in approximately 30% and 23% of human breast cancer tumor samples, respectively. Interestingly, Overexpression of EGFR and Overexpression of Her-2/Neu do not overlap in most of breast cancer tumor samples. These results suggested that patients with breast cancers should receive different treatments based on their gene expression profiles. For example, breast cancer patients carrying tumors with overexpression of Her-2/Neu should be treated with Her-2/Neu antagonists such as Herceptin, while patients carrying tumors with overexpression of EGFR should be treated with EGFR antagonists.				
14. SUBJECT TERMS breast cancers, Bcl-x, EGFR			15. NUMBER OF PAGES 7	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover	1
SF 298	2
Introduction	4
Body	4
Key Research Accomplishments	4-5
Reportable Outcomes	5
Conclusions	5-6
References	6
Appendices	7

INTRODUCTION

Most human breast cancer cells are derived from epithelial cells. Previously studies indicated that about 20% of breast cancer patients carrying tumor cells with overexpression of Her-2/Neu. Herceptin, an antagonist antibody against Her-2/Neu, has been used in clinic for the treatment of breast cancers overexpressing Her-2/Neu. However, most of breast cancers with normal levels of Her-2/Neu do not response well with Herceptin. The mechanisms for the development of these breast cancers need to be elucidated in order to design alternative approaches.

BODY

This proposed research was based on our previous studies on potential mechanism for the development of nasopharyngeal carcinoma (NPC). Most of NPC are associated with Epstein-Barr Virus (EBV). We hypothesized that the EBV-encoded Latent Membrane Protein 1 (LMP-1)-mediated up-regulation of both the pro-proliferative molecule, EGFR, and the anti-apoptotic protein, Bcl-XL, are key events in the formation of EBV-associated malignancies. Accordingly, we obtained EBV-positive biopsy specimens of NPC and stained them for LMP-1, EGFR, and Bcl-XL. In all cases, we found that both EGFR and Bcl-XL were strikingly up-regulated in the tumor, but not in the surrounding normal tissues (unpublished data). These results confirm those reported by Sheen et. al. in which they found that roughly 70% of NPC tumors stained positively for both LMP-1 and EGFR. We have suggested that EGFR as a potential therapeutic target to treat human patients carrying NPC.

The new discovery of EBV association with breast cancer led us to the hypothesis that LMP-1-mediated up-regulation of EGFR and Bcl-XL may also contribute to the formation of malignant breast cancer. Recent studies detecting the viral protein EBNA-1 have shown a highly variable incidence (0 to 50%) of EBV in breast cancer biopsies. To determine the levels of EGFR and the pro-survival Bcl-XL protein, we will perform immunohistochemical stainings on LMP-1 expressing tumors, using normal breast tissue biopsies as controls. If, as expected, EGFR and Bcl-XL are overexpressed in breast tumors, we will gain information as to the etiology of these tumors and will also be presented with a new therapeutic target for the treatment of breast cancer. Xenograph models would then be used to test the efficacy of EGFR as a therapeutic target for breast cancer. It is our vision that this work will lead to clinical trials using EGFR as a target for novel therapy for breast cancer.

KEY RESEARCH ACCOMPLISHMENTS

We have obtained over 30 human breast cancer samples from UCLA tissue bank. We have used the immunohistochemical staining method to detect the expression of determine their expression of EGFR, Her-2/Neu and Bcl-x in tumor cells and their surrounding normal tissues

with the corresponding antibodies. We have converted the expression levels of EGFR, Her-2/Neu and Bcl-x into numeric scales from 0, 1+, 2+, 3+ representing no staining, weak staining, strong staining, and highly overexpressed.

REPORTABLE OUTCOMES

Specimen #	EGFR		HER-2NEU		BCL-X	
	Non-tumor	Tumor	Non-tumor	Tumor	Non-tumor	Tumor
S01-3086		3+		0		3+
S01-15814	1+	1+	0	0	1+	3+
S01-11043	0	1+	0	0	2+	2+
S01-14826		0		1		2+
S01-8859	0	0	0	2+	2+	3+
S01-5983	0	1+	0	2+	2+	3+
S01-16364	0	2+		0	0	3+
S01-8752		2+		1		3+
S01-7079		1+		0		3+
S01-14316		0		1		3+
S01-7814	2+	0		0	3+	3+
S01-2427	1+	0		1	3+	3+
S01-15729		1+		0		2+
S01-1230		1+		1		3+
S00-20922	1+	2+		2+	3+	3+
S00-18452		1+		1		3+
S00-16106	0	0		2+	2+	3+
S00-8906		0		1		3+
S00-509		3+		1		2+
S00-482		2+		1		3+
S99-22690		0		0		3+
S99-20319		2+		0		3+
S99-18130	0			0	2+	3+
S99-17231	0					2+
S01-10274	0	0		2+	2+	3+
S01-6851	0	1+		0	2+	3+
S00-12837	0	2+		2+	3+	3+
S01-12592	1+	0		2+	2+	3+
S01-5741	1+	2+		1	2+	3+
S01-6322		0		0		3+

CONCLUSIONS

1. We found that EGFR is highly overexpressed (equal or greater than 2+) in tumor cells in approximately 30% of human breast cancer tumor samples.

2. Her-2/Neu is expressed higher (2+) in tumor cells than their surrounding normal cells in approximately 23% of human breast cancer tumor samples.
3. Overexpression of EGFR and Overexpression of Her-2/Neu do not overlap in most of breast cancer tumor samples. These results suggested that patients with breast cancers should receive different treatments based on their gene expression profiles. For example, breast cancer patients carrying tumors with overexpression of Her-2/Neu should be treated with Her-2/Neu antagonists such as Herceptin, while patients carrying tumors with overexpression of EGFR should be treated with EGFR antagonists. Our studies also raised several interesting questions for future studies: 1). Is overexpression of one members of the EGFR family sufficient to lead to the development of malignancies? 2). Is overexpression of EGFR or Her-2/Neu in human breast cancers related to the geographic locations or ethic background of patients? 3). What are the molecular mechanisms of EGFR and Her-2/Neu overexpression? Is EGFR overexpression related to EBV infection?
4. Bcl-x is expressed in both normal breast tissues and tumor cells, but its levels in breast cancer cells are higher in many cases than normal breast tissues.

REFERENCES

- Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. *Proc Natl Acad Sci U S A*. 1999 Aug 3;96(16):9136-41.
- Sheen TS et al. Epstein-Barr virus-encoded latent membrane protein 1 co-expresses with epidermal growth factor receptor in nasopharyngeal carcinoma. *Jpn J Cancer Res*. 1999 Dec;90(12):1285-92.
- Bonnet M, Guinebretiere JM, Kremmer E, Grunewald V, Benhamou E, Contesso G, Joab I. Detection of Epstein-Barr virus in invasive breast cancers. *J Natl Cancer Inst*. 1999 Aug 18;91(16):1376-81.
- Nicholson LJ et al. Epstein-Barr virus latent membrane protein does not inhibit differentiation and induces tumorigenicity of human epithelial cells. *Oncogene*. 1997 Jul 17;15(3):275-83.
- Kim H, Muller WJ. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. *Exp Cell Res*. 1999 Nov 25;253(1):78-87.

APPENDICES

